With this research project, we will investigate the effects of smoking and oxidative stress on epithelial barrier function in patients with asthma and COPD.The most important research questions are:1) Does exposure of cultured human epithelial cells…
ID
Source
Brief title
Condition
- Bronchial disorders (excl neoplasms)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
- changes in epithelial integrity as measured with electrical cell impedance
(ECIS) (during various conditions, i.e. with and without exposure to oxidative
stress, with and without treatment with corticosteroids, with and without
treatment with acetylcysteine, theophylline, heme oxygenase, carbon monoxide).
Secondary outcome
- production of pro-inflammatory cytokines during various conditions.
- markers of epithelial integrity (e.g. E-cadherin, caveolin-1) during various
conditions.
- In biopsies the macroscopic quality of the bronchial epithelium will be
assessed. In addition, we will investigate the expression of E-cadherin,
caveolin-1 and heme-oxygenase.
Background summary
Asthma and COPD are chronic inflammatory airway diseases affecting millions of
people worldwide. Inhaled corticosteroids (ICS) are by far the most effective
treatment with a broad anti-inflammatory spectrum. Nevertheless, most COPD
patients and a proportion of severe asthma patients are
corticosteroid-resistant (CR) and to fail to respond to ICS even when higher
doses are given. These corticosteroid-resistant patients suffer from persistent
symptoms and repeated asthma exacerbations. It has been suggested that smoking
and oxidative stress may induce corticosteroid-resistance. The reactive oxygen
species (ROS) responsible for oxidative stress can be generated exogenously
(air pollutants, cigarette smoke) and endogenously by metabolic reactions.
After inhaling air pollutants or cigarette smoke, the bronchial epithelium is
exposed. Preliminary data from our own lab suggest that smoking and oxidative
stress may decrease epithelial cell-cell contact formation. This results not
only in a decreased barrier function, but also in an increased production of
pro-inflammatory mediators.
Study objective
With this research project, we will investigate the effects of smoking and
oxidative stress on epithelial barrier function in patients with asthma and
COPD.
The most important research questions are:
1) Does exposure of cultured human epithelial cells to cigarette smoke or
oxidative stress decrease cell-cell contact formation and reduce the level of
caveolin-1?
2) Does exposure to cigarette smoke or oxidative stress render human cultured
bronchial epithelial cells less sensitive to the positive effects of
corticosteroids ?
3) Can the effects of smoking/oxidative stress on cultured human bronchial
epithelial cells be counteracted by (combinations of) corticosteroids, *2-
agonists, heme oxygenase-1, exposure to carbon monoxide, or vitamin D3? Is this
associated with an increase in caveolin-1?
4) What are the effects of modulation of caveolin-1 on cell-cell contact
formation?
5) Are there differences with respect to the above between patients with
allergic or non-allergic asthma, COPD, or healthy subjects?
6) Are there differences between cultured epithelial cells derived from
bronchial brushing and epithelial cells derived from nasal brushing?
Study design
This is an observational study. We will include a total of 60 well
characterized (lung function, PC20 methacholine, skin prick test) patients with
asthma and COPD. We will perform nasal and bronchial brushings. In addition,
bronchial biopsies are taken to investigate the level of epithelial shedding
and markers of epithelial integrity such as E-cadherin and caveolin-1. In
addition, we will investigate the expression of heme oxygenase 1.
Cultured epithelial cells will be stimulated with relevant inflammatory
mediators (e.g. TNF-*., IL-13) and the production of pro-inflammatory mediators
TARC, TSLP, IL-6, GM-CSF will be assessed in the presence and absence of
budesonide. Next, oxidative stress will applied by maintaining subconfluent
cells for 24 (or 48 hours) under 5% CO2/95% O2 which results in the production
of ROS. This allows us to investigate the effects of oxidative stress on
development corticosteroid resistance and the underlying mechanisms involved
(i.e. effects on the level of NF-*B (both cytoplasma and nucleus),
glucocorticoid receptor (GR)* and GR*, glucocorticoid responsive element (GRE),
HDAC-2, and p38 MAPK). Finally, we will assess the effects of treatment aimed
to protect against oxidative stress (e.g. N-acetylcysteine, upregulation of
HO-1 (protoporphyrin, adenoviral constructs), CO, curcumin, and resveratrol).
Finally, we will investigate the effects of treatment aimed to improve
corticosteroid responsiveness (e.g. *2-agonists, theophylline).
Study burden and risks
This study is not associated with large risks. Possible adverse reactions may
be:
- Blood collection may be painful and cause skin bruising.
- The provocation test with metahcholine may cause temporary dyspnea.
- The bronchoscopy may cause irritation of the airways and the bronchial biopsy
may cause local bleeding.
- The nasal brush may cause irritation of the nasal mucosa and may cause local
bleeding.
Hanzeplein 1
9713 GZ Groningen
Nederland
Hanzeplein 1
9713 GZ Groningen
Nederland
Listed location countries
Age
Inclusion criteria
inclusion criteria for patients with allergic asthma : ;* Age between 18 and 65 years.
* * 10 packyears, no smoking in the last year.
* The presence of allergy defined as at least one positive wheal/flare reaction (*2 mm relative to control) to a skin prick test with sixteen common aero-allergens).
* FEV1 > 80% predicted.
* PC20 methacholine or PC20 histamine < 8 mg/ml.;inclusion criteria for patients with COPD :
* Age between 45-75 years.
* * 10 packyears.
* FEV1 between 30% and 80% of predicted.
Exclusion criteria
*Any disease that, as judged by the Investigator, could have affected the outcome of this study.
*A respiratory tract infection within 4 weeks of the start of the study.
*A history of life-threatening asthma, defined as exacerbation of asthma or COPD that required intubation or was associated with hypercapnea.
*History of myocardial infarction or documented myocardial ischemia.
*Pregnancy, or the possibility of being pregnant (a pregnancy test will be performed in women of childbearing potential who do not use adequate anticonception as judged by the investigator).
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
ClinicalTrials.gov | NCT00849433 |
CCMO | NL26606.042.09 |